

**Breakthrough Technologies in Tissue Vitality** 

Prof. Avraham Mayevsky, CSO



# Management



Prof. Avraham Mayevsky, PhD
CSO
Professor Emeritus at Bar Ilan
University in Israel.
World leader in monitoring of
physiological activities in the brain
and in tissue.
More than 240 academic publications.



Dr. David Platt, PhD
CEO
Founder of five public companies.
Author of > 50 patents.
Numerous academic publications.



Ola Soderquist, CPA, CMA
CFO
30 years of Executive Leadership
in public and private organizations.
MBA from Babson College.




# **Clinical Unmet Need**

		Compartment	Oxygen level (mmHg)	Monitored Parameter			
	N <sub>2</sub>	Atmospheric Air	160	21% O <sub>2</sub> in Air			
				Systemic Vital Signs			
Systemic Monitoring		Respiratory System	100	Respiratory Rate & Volume End-Tidal CO <sub>2</sub> (ET-CO <sub>2</sub> )			
ystemic Monito		Cardiovascular System	95	Heart Rate (HR) Electrocardiogram (ECG) Cardiac Output (CO) Systemic Blood Pressure (BP)			
S		Macro-circulation		Systemic Hb Saturation (SaO <sub>2</sub> )			
				Microcirculatory Oxygen Supply ——			
Monitowing		Tissue Microcirculation	20- 30	Tissue Blood Flow (TBF) Tissue Blood Volume (TBV) Microcirculatory Oxygenation (HbO <sub>2</sub> )			
/ éific N	0.00			Tissue Oxygen Balance			
Speći		Intracellular	1- 2	Mitochondrial NADH Redox State			



# **Continuous Real-time In-vivo Tissue Spectroscopy**






# **Technology**

#### The MDX-Viewer consists of three components:

Main unit: contains the light source, optical detectors and the main signal processing components.

Monitor unit: displays the tissue monitored parameters and contains the MDX-Viewer operating user interface.

<u>Probe accessory:</u> contains the optical sensing flexible fiber bundle, connected to the main unit through an optical connector. The probe is integrated into an unique 3 way urinary (Foley) catheter.





## **Initial Market Potential USA**

### **MDX-Viewer-ICU**

- 6,000 ICUs
  - 90,000 beds (MDX-Viewer units potential)
  - 6 million admissions/year (Foley-Probes potential / Year)
  - \$5,000 per day cost (cost saving base)

## **MDX-Viewer-NICU**

- 12% premature (before 37th week of pregnancy), low-weight neonates
- 500,000 babies/year in US (15 million worldwide)
- 22,000 beds in US (MDX-Viewer units potential)

Total addressable market size: \$2.8 billion in Capital Equipment, and \$1.2 billion in Annual Recurring Revenue.

**Capital Equipment per Patient Bed** 





Disposable non-Reusable Probes per (N)ICU Patient






# The next generation: MDX-Viewer-TMS

A prognostic Big Data platform built on blockchain technology and supported by machine learning and AI. The device integrates monitored parameters and systemic vital signs presenting a combined Tissue Metabolic Score serving as a preemptive warning signal of body oxygen homeostasis.

#### Monitoring in OR's and ICU's/NICU's






# No competitors in NADH or Fully Integrated Monitoring

	Organ/System	Monitored Parameter	Cheetah Medical		SWEETE CONTRACTOR	/	
Systemic Monitoring	Systemic Vital Signs		Drager Edan Instruments		L65 es 1	/	1
	Respiratory System	Respiratory Rate & Volume End-Tidal CO <sub>2</sub> (ET-CO <sub>2</sub> )	Edwards Lifesciences GE Healthcare LiDCO		R67 66 1 S. 70 70 I S. 30 60 I	j J	ated
	Cardiovascular System	Heart Rate (HR) Electrocardiogram (ECG) Cardiac Output (CO) Systemic Blood Pressure (BP)	Masimo Medtronic Nihon Kohden Philips Pulsion Medical Sy				Integrated
	Macro-circulation	Systemic Hb Saturation (SaO <sub>2</sub> )	Spacelabs Healthcare Welch Allyn		```		
Specific Monitoring		Comparative Models	Moor - moorVMS-LDF Omegawave - Omegaflo Transonic - Costatus Vasamed - SensiLase	Perimed - PeriCam PSI	Cas Medical - Fore-Sight Hutchinson - InSpectra Masimo - SedLine Medtronic - INVOS Moor - moorVMS-NIRS Nonin - Equanox Omegawave - Bom-L1TRW Spectros - T-Stat	MDX-Viewer ICU	MDX-Viewer TMS
	Tissue Oxygen Supply						
	Tissue Microcirculation	Tissue Blood Flow (TBF)			×	<b>\</b>	<b>\</b>
		Tissue Blood Volume (TBV)	×		×	<b>\</b>	Vi
		Microcirculatory Oxygenation (HbO <sub>2</sub> )	×	X			
				1			
	Intracellular	Mitochondrial NADH Redox State	×	×	×	<b>\</b>	



# **Development Plan**

#### R&D, Regulatory and Marketing pathway



#### MDX Life Sciences, Inc.

233 Needham St., Suite 300 Newton MA, 02464 +1-(617)-454-1199 www.mdxlifesciences.com info@mdxlifesciences.com



**Breakthrough Technologies in Tissue Vitality** 

Prof. Avraham Mayevsky, CSO avraham.mayevsky@mdxlifesciences.com +972-(54) 486-1854